MedTrace Logo

Metronomic Oral Vinorelbine in Patients With Metastatic Tumors

NCT00278070 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2008-02-29

No results posted yet for this study

Summary

Patients with recurrent or metastatic solid tumors receive oral vinorelbine at one of three different doses (30 or 40 or 50 mg). Vinorelbine will be administered orally at a metronomic schedule three times a week: on Monday, Wednesday and Friday.

Conditions

Interventions

DRUG

vinorelbine oral formulation

Patients will take three times a week \[Monday, Wednesday and Friday\] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure

Sponsors & Collaborators

  • University of Ioannina

    collaborator OTHER

  • Hellenic Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Evangelos Briasoulis, MD · Assistant Professor of Oncology, Medical School, University of Ioannina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Completion
2008-02-29

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00278070 on ClinicalTrials.gov